VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2018 | Results from CAR T-cell bb2121 first-in-human trial for R/R MM

The anti-BCMA CAR T-cell therapy bb2121 looks extremely promising in multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General Hospital Cancer Center, Boston, MA, discusses the results of CRB-401 (NCT02658929), a first-in-human trial of bb2121 in relapsed/refractory MM, which were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL. Prof. Raje also highlights avenues for further study and the key questions that remain to be answered.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter